ALAMAST
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Sep 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALAMAST is an ophthalmic solution approved in 1999 for eye allergies and related conditions. It is a small-molecule mast cell stabilizer delivered as eye drops. The drug prevents allergic cascade initiation at the ocular surface.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating potential team restructuring and defensive commercial strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ALAMAST roles are concentrated in Commercial and Finance functions across Asia-Pacific, reflecting Santen's regional footprint and the product's lifecycle stage. Career opportunities emphasize cost management, regulatory compliance, and market defense rather than growth initiatives.
[Singapore] Head of FP&A[Singapore] Global Safety Vigilance Risk Management Lead
Worked on ALAMAST at Santen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.